SOCIAL CONTRIBUTION

Under the theme of our management vision of 'Health and Environment', we, Sanyei Corporation is dealing with the brand products from all over the world that has not only environemntal perspectives but also for local societies.

BOHONOMAD

BOHONOMAD is the Turkish Rope-sandal brand from Köyceğiz, Muğla Province, where located in the Aegean region of Turkey with the concept of "Sustainable/Eco-friendly", "Vegan", "Socially Responsible" and "100% Hand-made". All items are 100 % hand-made by Turkish women by using recyclable materials.

In the past time in Köyceğiz, Muğla Province in Turkey, it was not easy for women to have stable and continuous work while it was usual for them to work in seasons. However, BOHONOMAD gives priority to employing women who could work agricultural industry as they could with the social responsibility awareness, healthy environment, and health insurance in official payments by providing them with good working conditions.

• 
• 

WOOLDOT

WOOLDOT is a Danish design brand founded in 2008 using 100% New Zealand wool and colored with non-toxit, non-allergic, and AZO free colors. WOOLDOT is all 100% hand-made by over a hundred ladies from Kathmandu, Nepal. WOODOT believes it is important to give "knowhow" back to the region and give them the opportunity for a good and independent life.

• 
• 

Sanyei has continually supported NPO Japan Multiple Sclerosis Society since 1977.

What is multiple sclerosis (MS)?

MS is a demyelinating disease of the central nervous system that causes numbness and paralysis in the hands and legs from a spinal cord or other disability, and it was designated as an intractable disease by the Ministry of Health, Labour and Welfare in 1972. There is variation in the incidence rate among races, and it occurs frequently in areas with high latitude. MS is common among Caucasians in Europe and North America, where it is said that there are 50 to 100 sufferers per 100,000 people. While the number of Japanese patients is on the rise every year, there are not any medical treatment methods for a complete recovery yet.

History of Sanyei Corporation and the JMSS

1977 Established the Japan Multiple Sclerosis Society

Started when an American friend of the founder and CEO (at that time) of Sanyei Corporation, the late Kunio Izumi, made an earnest appeal to establish a multiple sclerosis society in Japan. The person who made this request was the Chairman of the Board of F.W. Woolworths Co. Ltd. (USA), one of SANYEI's clients at the time that had one of the world's largest retail businesses in North America.

Later, Mr. Izumi established the Japan Multiple Sclerosis Society in 1977 with the full support of related organizations including the Japanese Red Cross Society, the Japan Medical Association, and the Kyushu University, and its office was opened within SANYEI.

1981 the MS World Conference of Neurology was hosted in Kyoto

It was held by the Japan Multiple Sclerosis Society in which more than 160 researchers and medical advisory group representatives from 19 countries had participated, it could be considered a very important event even by current standards.

• The MS World Conference Kyoto in 1981
• SANYEI's founder, Mr. Izumi (second person from the left) at the MS World Conference
• Event to raise awareness in Asakusa held on the World Multiple Sclerosis Day in 2015
• Lecture meeting for local citizens held every year In 2015, a team of patients from France visited Japan for the program

In addition to events like this, the Japan Multiple Sclerosis Society has continued activities up to the present aimed at ending multiple sclerosis, providing partial subsidies for research expenses in Japan and conducting PR activities for multiple sclerosis as an internationally recognized member of the Multiple Sclerosis International Federation.

While the number of sufferers of multiple sclerosis is unfortunately on the rise in Japan, SANYEI will continue to support the activities of the Japan Multiple Sclerosis Society going forward in the hopes that there will be further advances in treatment methods and research on the causes of the disease.